Active Recombinant Cynomolgus CD3E & CD3D Protein, His-Avi-tagged, Biotinylated

• Cat.No.: CD3E & CD3D-516C
• Product Overview: Biotinylated Recombinant Cynomolgus CD3E & CD3D Protein, fused to His and Avi tag, was expressed from HEK293.

Specification

• Source: HEK293
• Species: Cynomolgus
• Tag: His-Avi
• Form: Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
• Bio-activity: Immobilized Bispecific T cell Engager (CD3 X BCMA) at 1 μg/mL (100 μL/well) can bind Biotinylated Cynomolgus CD3E&CD3D Heterodimer Protein, His,Avitag&Tag Free with a linear range of 0.5-3.9 ng/mL.
• Molecular Mass: The protein has a calculated MW of 17.8 kDa (CD3E) and 13.5 kDa (CD3D). Subunit CD3E is fused with a polyhistidine tag and followed by an Avi tag (Avitag™) and subunit CD3D contains no tag at the C-terminus. The reducing (R) heterodimer protein migrates as 21-23 kDa (CD3E) and 19-21 kDa (CD3D) due to glyosylation.
• Protein Length: Gln 22 - Asp 117 (CD3E) & Phe 22 - Ala 105 (CD3D)
• Endotoxin: Less than 1.0 EU per μg by the LAL method.
• Purity: >90% as determined by SDS-PAGE.
  >90% as determined by SEC-MALS.
• Storage: For long term storage, the product should be stored at lyophilized state at -20 centigrade or lower.
  Please avoid repeated freeze-thaw cycles.
  This product is stable after storage at:
  -20 centigrade to -70 centigrade for 12 months in lyophilized state;
  -70 centigrade for 3 months under sterile conditions after reconstitution.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4℃ before opening to recover the entire contents.

Reviews

03/22/2023

Manufacturers with the capacity for bulk production can offer CD3E protein in larger quantities, which is advantageous for researchers working on large-scale experiments or collaborations.

09/12/2021

bulk production often leads to economies of scale, making the CD3E protein more cost-effective for research budgets.

06/17/2018

Manufacturers can actively seek collaborations and partnerships with researchers to develop new applications or optimize methodologies using CD3E protein.

Q&As

Can CD3E be used to assess the effectiveness of cancer immunotherapies?

Yes, CD3E levels and T-cell function can be monitored to evaluate the response to cancer immunotherapies like checkpoint inhibitors.

Are there any CD3E-targeted therapies?

There are currently no approved therapies that directly target CD3E, but it is a target for research in developing immunotherapies and cancer treatments.

Are there any ongoing clinical trials involving CD3E?

There may be ongoing clinical trials using CD3E-targeted therapies in the context of cancer and autoimmune diseases. It's important to check clinical trial databases for specific studies.

Can CD3E levels be used to monitor the progression of HIV?

Yes, monitoring CD3E levels in HIV-infected individuals can provide valuable information about the progression of the disease and the effectiveness of antiretroviral therapy.

How is CD3E used in allergy diagnostics?

CD3E can be used in research to study T-cell responses in allergic conditions, helping to better understand and diagnose allergies.